Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
Office: bldg. E35/186
Kamenice 753/5
625 00 Brno
Phone: | +420 532 23 5494 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 74
2022
-
Prediction of novel treatment options for CLL and AML cells based on drug repurposing.
Year: 2022, type: Conference abstract
-
Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing.
Year: 2022, type: Conference abstract
-
The use of functional genomics for advancing monoclonal antibody therapy of chronic lymphocytic leukemia
Year: 2022, type:
2021
-
CD19 hypermethylation as an escape to CART-19.
Year: 2021, type: Conference abstract
-
CD19 promoter hypermethylation as means of antigen-negative escape to CART-19 therapy.
Year: 2021, type: Conference abstract
-
CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cells.
Year: 2021, type:
-
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
International Journal of Molecular Sciences, year: 2021, volume: 22, edition: 11, DOI
-
Drug repositioning in genetically defined CLL cases reveals a potentional novel therapeutic use for approved drugs.
Year: 2021, type: Conference abstract
-
Functional analysis of germlineETV6 W380Rmutation causing inherited thrombocytopenia and secondary acute lymphoblastic leukemia or essential thrombocythemia
Platelets, year: 2021, volume: 32, edition: 6, DOI
-
Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro
Journal for ImmunoTherapy of Cancer, year: 2021, volume: 9, edition: 8, DOI